PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-4 (4)
 

Clipboard (0)
None
Journals
Authors
more »
Year of Publication
Document Types
1.  Osteooncology – Specific Aspects in Breast Cancer Patients 
Breast Care  2010;5(5):288-289.
doi:10.1159/000321963
PMCID: PMC3132951  PMID: 21779209
2.  Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio 
Breast Care  2009;4(3):155-161.
Summary
Endocrine therapy has become a key part in the adjuvant treatment of hormone responsive breast cancer. The positive effect on relapse risk reduction is well defined, but therapy is not free from bothersome side effects for which estrogen deprivation accounts to a great extent. Since endocrine therapy is usually prescribed for 5 years or longer to optimally display its protective effect, and because physical strain is missing, good tolerability and safety properties are important, particularly in low-risk patients. While tamoxifen has been the standard adjuvant endocrine treatment with well documented efficiency, it is increasingly replaced by third generation aromatase inhibitors due to their better effectiveness and tolerability. Because tamoxifen holds a risk for life-threatening adverse events such as endometrial cancer, pulmonary embolism, and stroke, its recommended duration of therapy is limited to 5 years, also because extension beyond that time did not produce a measurable advantage. While some side effects are present both with tamoxifen and aromatase inhibitors, differences in side effect profiles are well established. Although side effects of aromatase inhibitor-related therapy usually are mild and common to symptoms of menopause, misconception of the symptoms and their mechanism of action, as well as lack of knowledge about how to handle them, can easily lead to dangerous discontinuation of therapy.
doi:10.1159/000227829
PMCID: PMC2931002  PMID: 21160541
Endocrine therapy; Breast cancer; Tamoxifen; Aromatase inhibitors; Anastrozole; Letrozole; Exemestane; Side effects; Tolerability; Safety
3.  The Future of Breast Cancer Management 
Breast Care  2008;3(6):381-382.
doi:10.1159/000185799
PMCID: PMC2931022  PMID: 21048905
4.  Breast Cancer in Developing Countries: Challenges for Multidisciplinary Care 
Breast Care  2008;3(1):4-5.
doi:10.1159/000115969
PMCID: PMC2931010  PMID: 20824012

Results 1-4 (4)